Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial.

Kazuki FuruhashiTomoyuki FujisawaDai HashimotoYousuke KamiyaHideki YasuiMasato KarayamaYuzo Suzuki Hironao HozumiNoriyuki EnomotoYutaro NakamuraNaoki InuiTakafumi Suda

Published in: Journal of asthma and allergy (2019)

The present study indicates that once-daily FF/VI DPI is not inferior to twice-daily BUD/FM DPI in clinical effect and more likely to improve inconvenience and forgetfulness in inhalation adherence barriers for stable asthma control therapy. Once-daily FF/VI DPI may be an effective alternative for asthma maintenance treatment.

Keyphrases

physical activity
chronic obstructive pulmonary disease
lung function
allergic rhinitis
clinical trial
stem cells
air pollution
study protocol
metabolic syndrome
combination therapy
open label
bone marrow
adipose tissue
weight loss
cell therapy
placebo controlled